Historical record - last NADAC effective date: 12/21/2016
Product Information
PERPHEN-AMITRIP 2 MG-25 MG TAB is a generic product labeled by Mylan Pharmaceuticals Inc., priced at $1.5059 per EA under NDC 00378044201. Its NADAC has been published 216 times since Nov 28, 2013.
FDA first approved this application on Nov 10, 1988.
Strength
25; 2 mg/1; mg/1
Manufacturer
Mylan Pharmaceuticals Inc.NDC
00378044201
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
12/21/2016
Active Ingredients
AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINEApproval Type
Generic (ANDA)
FDA Application
ANDA071443FDA Approved
11/10/1988
On Market Since
11/10/1988
Pharmacological Classes
Price Statistics
The NADAC for PERPHEN-AMITRIP 2 MG-25 MG TAB has been published 216 times since Nov 28, 2013, and over the history we have for it it has risen 111.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.5059 per EA |
|---|---|
| All-time high | $1.5952 (Oct 12, 2016) |
| All-time low | $0.7122 (Nov 28, 2013) |
| Median price | $1.2981 |
| Average price | $1.2443 |
| Largest weekly change | +47.4% (Jun 18, 2014) |
| Weeks tracked | 216 |
| Tracking since | Nov 28, 2013 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
N/A
5Y
N/A
All
+111.4%
Last surveyed Jan 10, 2018 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the perphenazine and amitriptyline hydrochloride market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Mylan Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
perphenazine and amitriptyline hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Phenothiazine class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of PERPHEN-AMITRIP 2 MG-25 MG TAB?
The current National Average Drug Acquisition Cost (NADAC) for PERPHEN-AMITRIP 2 MG-25 MG TAB, manufactured by Mylan Pharmaceuticals Inc., is $1.5059 per EA (NDC 00378044201), effective Jan 10, 2018.
How has the price of PERPHEN-AMITRIP 2 MG-25 MG TAB changed over time?
Over the history we have for it, the NADAC for PERPHEN-AMITRIP 2 MG-25 MG TAB has risen 111.4%. It has been tracked across 216 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for PERPHEN-AMITRIP 2 MG-25 MG TAB?
Since Nov 28, 2013, the NADAC for PERPHEN-AMITRIP 2 MG-25 MG TAB has ranged from a low of $0.7122 (Nov 28, 2013) to a high of $1.5952 (Oct 12, 2016), with a median of $1.2981 per EA.
Are there cheaper alternatives to PERPHEN-AMITRIP 2 MG-25 MG TAB?
No other NADAC-published product currently shares the active ingredient and strength of PERPHEN-AMITRIP 2 MG-25 MG TAB in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures PERPHEN-AMITRIP 2 MG-25 MG TAB?
PERPHEN-AMITRIP 2 MG-25 MG TAB (NDC 00378044201) is labeled by Mylan Pharmaceuticals Inc., and CMS classifies it as a generic product.